A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung

Trial Profile

A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs CD40L GVAX (Primary) ; Cancer vaccine
  • Indications Adenocarcinoma; Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 31 Dec 2017 to 28 Feb 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Apr 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top